at heavily discounted prices so repatha's sales came under pressure and they cut their own prices by 60% recently to get in line with competition. why am i so excited about a huge price cut which wouldn't normally sound like an act of desperation, right because according to amgen three-quarters of medicare patients never even fill the repatha prescriptions because it's so darn expensive that should give the drug a major boost. you cut the price but expand the universe by so many people, it's going to work. why the announcement -- that's why when the initially got hit on the stock it rallied. i believe we'll hear a lot of good studies that say far more people should be on it because everybody can benefit from much lower cholesterol. the bottom line, amgen is taking control of its own destiny and with it selling -- it's only 13 times earnings i think this one could have a lot more room to run let's go to bill in south carolina bill >> caller: yes, sir. boo-yah, jim. >> boo-yah, bill

doesn't america have a horrible obesity epidemic but when repatha got approval back in 2015 tsarnaevt was expensive and cost $14,000 a year the new drugs are superior to old-fashioned statins like lipitor that i can't take and more effective at preventing strokes and fewer side effects should have been a slam dunk but most statins are generic and only cost a few hundred bucks. both of these ended up disappointing. by 2017 repatho generated $19 million sales, but people thought it would be a billion dollar blockbuster early this year things got worst when san fofee decide to sell it at heavily discounted prices so repatha's sales came under pressure and they cut their own prices by 60% recently to get in line with competition. why am i so excited about a huge price cut which wouldn't normally sound like an act of desperation, right because according to amgen three-quarters of medicare patients never even fill the repatha prescriptions because it's so darn expensive that should give the drug a major boost. you cut the price but expand the universe by so many people, it's going to work.

. >> i think there is competition of repatha from amgen. and we used to have him on it is a very high risk but high reward situation i am not going to fight you on it because you know how i feel about these incredible wonder drug companies with mad money. as long as you can afford to lose the money, you will be fine make sure you vote nucor is down a few bucks. so what the heck is happening. we are going to talk about the ceo about trump and trade. cutting the core of apple tonight. and you know i am on the lookout for a good disruptor story and tonight i found one on the communication base and i will reveal the name so stay with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on twitter have a question? tweet cramer, #madtweets send jim an e-mail to madmoney@cnbc.com or give us a call at 1-800-743-cnbc miss something head to madmoney.cnbc.com. your brain is an amazing thing. but as you get older, it naturally begins to change, causing a lack of sharpness, or even trouble with recall. thankfully, the breakthrough